A20 interacts with mTORC2 to inhibit the mTORC2/Akt/Rac1 signaling axis in hepatocellular carcinoma cells

被引:2
|
作者
Wang, Xinyu [1 ,2 ]
Xiao, Ying [3 ]
Dong, Yanlei [1 ,2 ]
Wang, Zhida [4 ]
Yi, Jing [1 ,2 ]
Wang, Jianing [1 ,2 ]
Wang, Xiaoyan [1 ,2 ]
Zhou, Huaiyu [5 ]
Zhang, Lining [1 ,2 ]
Shi, Yongyu [1 ,2 ]
机构
[1] Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Dept Immunol, Jinan 250012, Shandong, Peoples R China
[2] Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Shandong Key Lab Infect & Immun, Jinan 250012, Shandong, Peoples R China
[3] Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Lab Cellular & Mol Med, Jinan, Peoples R China
[4] Shandong Second Prov Gen Hosp, Dept Clin Lab, Jinan, Peoples R China
[5] Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Dept Pathogen Biol, Jinan, Peoples R China
关键词
ENDOMETRIAL CANCER-CELLS; KAPPA-B ACTIVATION; UBIQUITIN LIGASE; ALPHA; LUBAC; RAC1; INACTIVATION; INFLAMMATION; RECRUITMENT; INDUCTION;
D O I
10.1038/s41417-022-00562-2
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
A20 acts as a tumor suppressor in hepatocellular carcinoma, especially inhibiting metastasis of the malignant cells. However, the mechanisms whereby A20 plays the inhibitory roles are not understood completely. Rac1 signaling is essential for cell migration in hepatocellular carcinoma metastasis. Nevertheless, it is not known whether and how A20 inhibits Rac1 signaling to suppress the migration of hepatocellular carcinoma cell. Thereby, we analyzed the relationship between A20 and Rac1 activation, as well as the activity of Akt and mTORC2, two signaling components upstream of Rac1, using gain and loss of function experiments. We found that the overexpression of A20 repressed, while the knockdown or knockout of A20 promoted, the activation of Rac1, Akt and mTORC2 in hepatocellular carcinoma cells. Moreover, the inhibitory effect of A20 on the mTORC2/Akt/Rac1 signaling axis was due to the interaction between A20 and mTORC2 complex. The binding of A20 to mTORC2 was mediated by the ZnF7 domain of A20 and M1 ubiquitin chain in the mTORC2 complex. Furthermore, A20 inhibited metastasis of hepatocellular carcinoma cells via restraining mTORC2 in a hepatocellular carcinoma xenograft mouse model. These findings revealed the relationship between A20 and mTORC2, and explained the molecular mechanisms of A20 in inhibition of hepatocellular carcinoma metastasis.
引用
收藏
页码:424 / 436
页数:13
相关论文
共 50 条
  • [41] MOLECULAR AND CLINICAL CHARACTERIZATION OF RICTOR (MTORC2) AS A CANDIDATE ONCOGENE IN HEPATOCELLULAR CARCINOMA
    Villanueva, A.
    Cornella, H.
    Tovar, V.
    Alsinet, C.
    Chiang, D.
    Peix, J.
    Minguez, B.
    Sara, T.
    Savic, R.
    Hoshida, Y.
    Lachenmayer, A.
    Thung, S.
    Roayaie, S.
    Schwartz, M.
    Jordi, B.
    Mazzaferro, V.
    Friedman, S.
    Llovet, J.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S45 - S45
  • [42] The role of mTORC1 and mTORC2 in UVB-induced
    Lewis, Martha
    Shantz, Lisa
    FASEB JOURNAL, 2013, 27
  • [43] mTORC1 and mTORC2 as regulators of cell metabolism in immunity
    Linke, Monika
    Fritsch, Stephanie Deborah
    Sukhbaatar, Nyamdelger
    Hengstschlaeger, Markus
    Weichhart, Thomas
    FEBS LETTERS, 2017, 591 (19): : 3089 - 3103
  • [44] Loss of mTORC2 signaling in oligodendrocyte precursor cells delays myelination
    Grier, Mark D.
    West, Kathryn L.
    Kelm, Nathaniel D.
    Fu, Cary
    Does, Mark D.
    Parker, Brittany
    McBrier, Eleanor
    Lagrange, Andre H.
    Ess, Kevin C.
    Carson, Robert P.
    PLOS ONE, 2017, 12 (11):
  • [45] Molecular and clinical characterization of RICTOR (MTORC2) as a candidate oncogene in hepatocellular carcinoma
    Villanueva, Augusto
    Cornelia, Helena
    Tovar, Victoria
    Alsinet, Clara
    Chiang, Derek
    Minguez, Beatriz
    Toffanin, Sara
    Savic, Rad
    Hoshida, Yujin
    Lechenmayer, Anja
    Thung, Swan
    Roayaie, Sasan
    Schwartz, Myron
    Bruix, Jordi
    Mazzaferro, Vincenzo
    Friedman, Scott
    Llovet, Josep
    CANCER RESEARCH, 2009, 69
  • [46] GILZ inhibits the mTORC2/AKT pathway in BCR-ABL+ cells
    Joha, S.
    Nugues, A-L
    Hetuin, D.
    Berthon, C.
    Dezitter, X.
    Dauphin, V.
    Mahon, F-X
    Roche-Lestienne, C.
    Preudhomme, C.
    Quesnel, B.
    Idziorek, T.
    ONCOGENE, 2012, 31 (11) : 1419 - 1430
  • [47] GILZ inhibits the mTORC2/AKT pathway in BCR-ABL+ cells
    S Joha
    A-L Nugues
    D Hétuin
    C Berthon
    X Dezitter
    V Dauphin
    F-X Mahon
    C Roche-Lestienne
    C Preudhomme
    B Quesnel
    T Idziorek
    Oncogene, 2012, 31 : 1419 - 1430
  • [48] MFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling
    Xu, Ke
    Chen, Guo
    Li, Xiaobo
    Wu, Xiaoqin
    Chang, Zhijie
    Xu, Jianhua
    Zhu, Yu
    Yin, Peihao
    Liang, Xin
    Dong, Lei
    SCIENTIFIC REPORTS, 2017, 7
  • [49] Combined Targeting of mTORC1 and mTORC2 Synergistically Inhibits Proliferation of Hepatocellular Carcinoma Cells: Effects of Everolimus and Ku0063794
    Kim, Say-June
    Choi, Ho-Joong
    Kim, Dong-Goo
    LIVER TRANSPLANTATION, 2014, 20 : S235 - S235
  • [50] MFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling
    Ke Xu
    Guo Chen
    Xiaobo Li
    Xiaoqin Wu
    Zhijie Chang
    Jianhua Xu
    Yu Zhu
    Peihao Yin
    Xin Liang
    Lei Dong
    Scientific Reports, 7